Clinical trial

Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC

NCT07703228

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2025-08-13

PhasePHASE2

Study timeline

Study start (actual)2025-08-13Date precision: day

Registry last updated2026-07-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)unresolved

NSCLC Stage IIIB~IVunresolved

Second-line Therapyunresolved

Metastasesunresolved

Interventions

Sacituzumab tirumotecanDRUG

Sponsors & collaborators

Nanfang Hospital, Southern Medical Universitylead sponsor

Affiliated Cancer Hospital & Institute of Guangzhou Medical Universitycollaborator

Shenzhen Hospital of Guangzhou University of Chinese Medicinecollaborator

The Central Hospital of Huanggangcollaborator

Department of Obstetrics and Gynecology, Affiliated Dongguan People's Hospital, Southern Medical Universitycollaborator

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07703228 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.